Cardiac xenotransplantation: Progress and challenges

Current Opinion in Organ Transplantation

Volumn 17, Issue 2, 2012, Pages 148-154

  Byrne, Guerard W ^a,b   McGregor, Christopher G A ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b MAYO CLINIC   (United States)

Author keywords

1,3 galactosyltransferase gene knockout; antibody mediated rejection; complement regulatory proteins; organ transplantation; transgenic; xenotransplantation

Indexed keywords

ALPHA 1,3 GALACTOSYLTRANSFERASE; ANTIBODY; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C4D; COMPLEMENT COMPONENT C5B; COMPLEMENT MEMBRANE ATTACK COMPLEX; GALACTOSYLGALACTOSE;

ANTIBODY RESPONSE; BLOOD CLOTTING; CARDIAC GRAFT REJECTION; COMPLEMENT DEPOSITION; GENE EXPRESSION; GENE MUTATION; GRAFT REJECTION; GRAFT SURVIVAL; HEART FUNCTION; HEART TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; HYPERACUTE GRAFT REJECTION; NONHUMAN; PERIOPERATIVE CARDIAC XENOGRAFT DYSFUNCTION; PERIOPERATIVE COMPLICATION; PERIOPERATIVE PERIOD; REVIEW; SWINE; XENOTRANSPLANTATION;

ANIMALS; GALACTOSYLTRANSFERASES; GENE EXPRESSION; GRAFT REJECTION; HEART FAILURE; HEART TRANSPLANTATION; PRIMATES; SWINE; THROMBOSIS; TISSUE DONORS; TRANSPLANTATION, HETEROLOGOUS; TRANSPLANTS;

EID: 84858797702     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3283509120     Document Type: Review

References (76)

1. Garbade J, Bittner HB, Barten MJ, Mohr FW. Current trends in implantable left ventricular assist devices. Cardiol Res Pract 2011; 2011:290561.
2. Atala A, Bauer SB, Soker S, et al. Tissue-engineered autologous bladders for patients needing cystoplasty. Lancet 2006; 367:1241-1246.
3. Ott HC, Matthiesen TS, Goh SK, et al. Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart. Nat Med 2008; 14:213-221. (Pubitemid 351214548)
4. d'Apice AJ, Cowan PJ. Xenotransplantation: the next generation of engineered animals. Transpl Immunol 2009; 21:111-115.
5. McGregor CG, Davies WR, Oi K, et al. Cardiac xenotransplantation: recent preclinical progress with 3-month median survival. J Thorac Cardiovasc Surg 2005; 130:844-851.
6. Phelps CJ, Koike C, Vaught TD, et al. Production of alpha 1,3-galactosyltransferase-deficient pigs. Science 2003; 299:411-414.
7. Dai Y, Vaught TD, Boone J, et al. Targeted disruption of the a1,3-galactosyltransferase gene in cloned pigs. Nat Biotech 2002; 20:251-255. (Pubitemid 34205417)
8. Sharma A, Naziruddin B, Cui C, et al. Pig cells that lack the gene for alpha1-3 galactosyltransferase express low levels of the Gal antigen. Transplantation 2003; 75:430-436. (Pubitemid 36241133)
9. Sandrin MS, Milland JA, Taylor S, et al. A second galactosyltransferase which synthesizes the major xenoepitope Gala(1,3)Gal. Xenotransplantation 2001; 8:27.
10. Nottle MB, Beebe LF, Harrison SJ, et al. Production of homozygous alpha-1,3-galactosyltransferase knockout pigs by breeding and somatic cell nuclear transfer. Xenotransplantation 2007; 14:339-344. (Pubitemid 47174364)
11. Diswall M, Angstrom J, Karlsson H, et al. Structural characterization of alpha1,3-galactosyltransferase knockout pig heart and kidney glycolipids and their reactivity with human and baboon antibodies. Xenotransplantation 2010; 17:48-60.
12. Kiernan K, Harnden I, Gunthart M, et al. The anti-nonGal xenoantibody response to xenoantigens on Gal knockout pig cells is encoded by a restricted number of germline progenitors. Am J Transplant 2008; 8:1829-1839.
13. Kuwaki K, Tseng YL, Dor FJ, et al. Heart transplantation in baboons using alpha1,3-galactosyltransferase gene-knockout pigs as donors: initial experience. Nat Med 2005; 11:29-31. (Pubitemid 40215833)
14. Tazelaar HD, Byrne GW, McGregor CG. Comparison of Gal and non-Galmediated cardiac xenograft rejection. Transplantation 2011; 91:968-975.
15. Shimizu A, Hisashi Y, Kuwaki K, et al. Thrombotic microangiopathy associated with humoral rejection of cardiac xenografts from alpha1,3-galactosyltransferase gene-knockout pigs in baboons. Am J Pathol 2008; 172:1471-1481. (Pubitemid 351793341)
16. Houser SL, Kuwaki K, Knosalla C, et al. Thrombotic microangiopathy and graft arteriopathy in pig hearts following transplantation into baboons. Xenotransplantation 2004; 11:416-425. (Pubitemid 39128211)
17. McGregor CGA, Teotia SS, Byrne GW, et al. Cardiac xenotransplantation: progress toward the clinic. Transplantation 2004; 78:1569-1575. (Pubitemid 39648427)
18. Manson JJ, Mauri C, Ehrenstein MR. Natural serum IgM maintains immunological homeostasis and prevents autoimmunity. Springer Semin Immunopathol 2005; 26:425-432. (Pubitemid 40468894)
19. Merbl Y, Zucker-Toledano M, Quintana FJ, Cohen IR. Newborn humans manifest autoantibodies to defined self molecules detected by antigen microarray informatics. J Clin Invest 2007; 117:712-718. (Pubitemid 46348529)
20. Galili U, Mandrell RE, Hamadeh RM, et al. Interaction between human natural anti-a-galactosyl immunoglobulin G and bacteria of the human flora. Infect Immun 1988; 56:1730-1737.
21. Ezzelarab M, Hara H, Busch J, et al. Antibodies directed to pig non-Gal antigens in naive and sensitized baboons. Xenotransplantation 2006; 13:400-407. (Pubitemid 44265708)
22. Rood PP, Hara H, Ezzelarab M, et al. Preformed antibodies to alpha1,3-galactosyltransferase gene-knockout (GT-KO) pig cells in humans, baboons, and monkeys: implications for xenotransplantation. Transplant Proc 2005; 37:3514-3515. (Pubitemid 41659938)
23. Byrne GW, Stalboerger PG, Davila E, et al. Proteomic identification of non-Gal antibody targets after pig-to-primate cardiac xenotransplantation. Xenotransplantation 2008; 15:268-276.
24. Ezzelarab M, Garcia B, Azimzadeh A, et al. The innate immune response and activation of coagulation in alpha1,3-galactosyltransferase gene-knockout xenograft recipients. Transplantation 2009; 87:805-812.
25. Mohiuddin MM, Corcoran PC, Singh AK, et al. Pig to baboon cardiac xenotransplantation: essential role of B cell depletion in prolonging cardiac xenograft survival. Am J Transplant 2010; 10 (Supplement):186.
26. Zhu A, Hurst R. Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum. Xenotransplantation 2002; 9:376-381. (Pubitemid 36358933)
27. Padler-Karavani V, Yu H, Cao H, et al. Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease. Glycobiology 2008; 18:818-830.
28. Saethre M, Baumann BC, Fung M, et al. Characterization of natural human anti-nonGal antibodies and their effect on activation of porcine Gal-deficient endothelial cells. Transplantation 2007; 84:244-250. (Pubitemid 47205759)
29. Hedlund M, Tangvoranuntakul P, Takematsu H, et al. N-glycolylneuraminic acid deficiency in mice: implications for human biology and evolution. Mol Cell Biol 2007; 27:4340-4346. (Pubitemid 46906558)
30. Yeh P, Ezzelarab M, Bovin N, et al. Investigation of potential carbohydrate antigen targets for human and baboon antibodies. Xenotransplantation 2010; 17:197-206.
31. Byrne GW, Stalboerger PG, Du Z, et al. Identification of new carbohydrate and membrane protein antigens in cardiac xenotransplantation. Transplantation 2011; 91:287-292.
32. Renton PH, Howell P, Ikin EW, et al. Anti-Sda, a new blood group antibody. Vox Sang 1967; 13:493-501.
33. Montiel MD, Krzewinski-Recchi MA, Delannoy P, Harduin-Lepers A. Molecular cloning, gene organization and expression of the human UDP-GalNAc: Neu5Acalpha2-3Galbeta-R beta1,4-N-acetylgalactosaminyltransferase responsible for the biosynthesis of the blood group Sda/Cad antigen: evidence for an unusual extended cytoplasmic domain. Biochem J 2003; 373 (Pt 2): 369-379. (Pubitemid 36897840)
34. Cesarman-Maus G, Rios-Luna NP, Deora AB, et al. Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome. Blood 2006; 107:4375-4382. (Pubitemid 43801363)
35. Al-Hashimi AA, Caldwell J, Gonzalez-Gronow M, et al. Binding of anti-GRP78 autoantibodies to cell surface GRP78 increases tissue factor procoagulant activity via the release of calcium from endoplasmic reticulum stores. J Biol Chem 2010; 285:28912-28923.
36. Van de Wouwer M, Collen D, Conway EM. Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol 2004; 24:1374-1383. (Pubitemid 39050428)
37. Kawakatsu T, Suzuki M, Kido H, et al. Antithrombotic effect of an antiglycoprotein IIB/IIIA antibody in primate lethal thrombosis. Thromb Res 1993; 70:245-254. (Pubitemid 23151331)
38. Cooper DKC, Keogh AM, Brink J, et al. Report of the Xenotransplantation Advisory Committee of the International Society for Heart and Lung Transplantation: the present status of xenotransplantation and its potential role in the treatment of end-stage cardiac and pulmonary diseases. J Heart Lung Transplant 2000; 19:1125-1165.
39. Waterworth PD, Dunning J, Tolan M, et al. Life-supporting pig-to-baboon heart xenotransplantation. J Heart Lung Transplant 1998; 17:1201-1207. (Pubitemid 29013401)
40. Vial CM, Ostlie DJ, Bhatti FNK, et al. Life supporting function for over one month of a transgenic porcine heart in a baboon. J Heart Lung Transplant 2000; 19:224-229. (Pubitemid 30088996)
41. Schmoeckel M, Bhatti FNK, Zaidi A, et al. Orthotopic heart transplantation in a transgenic pig-to-primate model. Transplantation 1998; 65:1570-1577. (Pubitemid 28304590)
42. Xu H, Gundry SR, Hancock WW, et al. Prolonged discordant xenograft survival and delayed xenograft rejection in a pig-to-baboon orthotopic cardiac xenograft model. J Thorac Cardiovasc Surg 1998; 115:1342-1349. (Pubitemid 28272629)
43. McGregor CGA, Davies WR, Oi K, et al. Recovery of cardiac function after pig-to-primate orthotopic heart transplant [abstract 98]. Am J Transplant 2008; 8 (S2):205-206.
44. Brandl U, Michel S, Erhardt M, et al. Transgenic animals in experimental xenotransplantation models: orthotopic heart transplantation in the pig-tobaboon model. Transplant Proc 2007; 39:577-578. (Pubitemid 46394577)
45. Brandl U, Michel S, Erhardt M, et al. Administration of GAS914 in an orthotopic pig-to-baboon heart transplantation model. Xenotransplantation 2005; 12:134-141. (Pubitemid 40314397)
46. McGregor CGA, Byrne GW, Vlasin M, et al. Cardiac function after preclinical orthotopic cardiac xenotransplantation. Am J Transplant 2009; 9 (S2):380.
47. Calne RY, Bitter-Suermann H, Davis DR, et al. Orthotopic heart transplantation in the pig. Nature 1974; 247:140-142.
48. Ryan JB, Hicks M, Cropper JR, et al. Cariporide (HOE-642) improves cardiac allograft preservation in a porcine model of orthotopic heart transplantation. Transplantation 2003; 75:625-631. (Pubitemid 36337359)
49. Candilio L, Hausenloy DJ, Yellon DM. Remote ischemic conditioning: a clinical trial's update. J Cardiovasc Pharmacol Ther 2011; 16:304-312.
50. Hing AJ, Watson A, Hicks M, et al. Combining cariporide with glyceryl trinitrate optimizes cardiac preservation during porcine heart transplantation. Am J Transplant 2009; 9:2048-2056.
51. Bhamra GS, Hausenloy DJ, Davidson SM, et al. Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening. Basic Res Cardiol 2008; 103:274-284.
52. Ashton KJ, Peart JN, Morrison RR, et al. Genetic modulation of adenosine receptor function and adenosine handling in murine hearts: insights and issues. J Mol Cell Cardiol 2007; 42:693-705. (Pubitemid 46527592)
53. Crikis S, Lu B, Murray-Segal LM, et al. Transgenic overexpression of CD39 protects against renal ischemia-reperfusion and transplant vascular injury. Am J Transplant 2010; 10:2586-2595.
54. Bollini S, Smart N, Riley PR. Resident cardiac progenitor cells: at the heart of regeneration. J Mol Cell Biol 2011; 50:296-303.
55. Bauer A, Postrach J, Thormann M, et al. First experience with heterotopic thoracic pig-to-baboon cardiac xenotransplantation. Xenotransplantation 2010; 17:243-249.
56. Byrne GW, Du Z, Sun Z, et al. Changes in cardiac gene expression after pig-to-primate orthotopic xenotransplantation. Xenotransplantation 2011; 18:14-27.
57. Berry GJ, Angelini A, Burke MM, et al. The ISHLT working formulation for pathologic diagnosis of antibody-mediated rejection in heart transplantation: evolution and current status (2005-2011). J Heart Lung Transplant 2011; 30:601-611.
58. Cowan PJ, Roussel JC, d'Apice AJ. The vascular and coagulation issues in xenotransplantation. Curr Opin Organ Transplant 2009; 14:161-167.
59. Siegel JB, Grey ST, Lesnikoski BA, et al. Xenogeneic endothelial cells activate human prothrombin. Transplantation 1997; 64:888-896. (Pubitemid 27422273)
60. Robson SC, Siegel JB, Lesnikoski BA, et al. Aggregation of human platelets induced by porcine endothelial cells is dependent upon both activation of complement and thrombin generation. Xenotransplantation 1996; 3: 24-34.
61. Lin CC, Chen D, McVey JH, et al. Expression of tissue factor and initiation of clotting by human platelets and monocytes after incubation with porcine endothelial cells. Transplantation 2008; 86:702-709.
62. Deaglio S, Robson SC. Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity. Adv Pharmacol 2011; 61:301-332.
63. Lin CC, Cooper DK, Dorling A. Coagulation dysregulation as a barrier to xenotransplantation in the primate. Transplant Immunol 2009; 21:75-80.
64. Schirmer JM, Fass DN, Byrne GW, et al. Effective antiplatelet therapy does not prolong transgenic pig to baboon cardiac xenograft survival. Xenotransplantation 2004; 11:436-443. (Pubitemid 39128213)
65. Byrne GW, Schirmer JM, Fass DN, et al. Warfarin or low-molecular-weight heparin therapy does not prolong pig-to-primate cardiac xenograft function. Am J Transplant 2005; 5:1011-1020. (Pubitemid 40571249)
66. Byrne GW, Davies WR, Oi K, et al. Increased immunosuppression, not anticoagulation, extends cardiac xenograft survival. Transplantation 2006; 82:1787-1791. (Pubitemid 46035668)
67. Cozzi E, Simioni P, Boldrin M, et al. Effects of long-term administration of high-dose recombinant human antithrombin in immunosuppressed primate recipients of porcine xenografts. Transplantation 2005; 80:1501-1510. (Pubitemid 41803634)
68. Simioni P, Boldrin M, Gavasso S, et al. Effects of long-term administration of recombinant human protein C in xenografted primates. Transplantation 2011; 91:161-168.
69. Petersen B, Ramackers W, Tiede A, et al. Pigs transgenic for human thrombomodulin have elevated production of activated protein C. Xenotransplantation 2009; 16:486-495.
70. Klymiuk N, Wuensch A, Kurome M, et al. GalT-KO/CD46/hTM tripletransgenic donor animals for pig-to-baboon heart transplantation. Xenotransplantation 2011; 18:271.
71. Iwamoto M, Yazaki S, Onishi A, et al. Successful production and breeding of cloned pigs expressing human thrombomodulin in endothelial cells. Xenotransplantation 2011; 18:270.
72. Ayares D, Phelps C, Vaught T, et al. Multitransgenic pigs for vascularized pig organ xenografts. Xenotransplantation 2011; 18:269.
73. Ahrens H, Petersen B, Cunha A, et al. Production and characterization of TF knock-down pigs and hTFPI transgenic pigs. Xenotransplantation 2011; 18:296.
74. Salvaris E, Fisicaro N, Harrison S, et al. Expression of human thrombomodulin in GTKO/hCD55-hCD59-HTF pigs. Xenotransplantation 2011; 18:296.
75. Perota A, Lagutina I, Colleoni S, et al. High ubiquitous hCD55 and hCD39 coexpression in live transgenic alpha 1,3-Gal knock-out piglet. Xenotransplantation 2011; 18:297.
76. McGregor CGA, Ricci D, Miyagi N, et al. Human CD55 expression blocks hyperacute rejection and restricts complement activation in Gal knockout cardiac xenografts. Transplantation 2012 in press.